GEOGRAPHIC ATROPHY
Clinical trials for GEOGRAPHIC ATROPHY explained in plain language.
Never miss a new study
Get alerted when new GEOGRAPHIC ATROPHY trials appear
Sign up with your email to follow new studies for GEOGRAPHIC ATROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Bionic eye implant aims to bring back sight in advanced macular degeneration
Disease control OngoingThis study tests a device called the PRIMA System, which includes an implant placed under the retina and a special visual processor worn by the patient. The goal is to help people with advanced dry age-related macular degeneration (geographic atrophy) regain some central vision. …
Matched conditions: GEOGRAPHIC ATROPHY
Phase: NA • Sponsor: Science Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Syfovre safety check: Real-World study tracks eye drug in 300 patients
Disease control OngoingThis study looks at how safe and tolerable the drug pegcetacoplan (Syfovre) is for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 300 patients who are already prescribed the drug by their doctor will be followed …
Matched conditions: GEOGRAPHIC ATROPHY
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Telescope eye implant study for AMD withdrawn before it began
Disease control TerminatedThis study planned to test a small telescope implant inside the eye for people with severe vision loss from advanced age-related macular degeneration (AMD). The device was meant to improve central vision by magnifying images onto healthy parts of the retina. However, the trial wa…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: NA • Sponsor: VisionCare, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New eye drug takes on leading cause of blindness in the elderly
Disease control OngoingThis study tests a new medicine called BI 771716 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 202 adults aged 50 and older will receive either the new drug or an existing treatment (pegcetacoplan) as eye injections. T…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New eye injection targets Blindness-Causing lesions
Disease control OngoingThis early-stage study tests the safety of an experimental drug called RO7669330, given as an injection into the eye, for people with geographic atrophy (GA) due to age-related macular degeneration (AMD). The study involves 27 participants and will monitor side effects and eye he…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New eye injection aims to stop vision loss in dry AMD patients
Disease control OngoingThis study tests whether monthly eye injections of ANX007 can prevent significant vision loss in people with dry age-related macular degeneration (AMD) that has progressed to geographic atrophy. About 659 participants will receive either the drug or a sham injection. The main goa…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE3 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug aims to slow vision loss in Age-Related blindness
Disease control OngoingThis study tests a drug called BI 1584862 in 150 adults aged 50+ with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. Participants receive either the drug or a placebo for 1 year. Doctors track changes in the retina using special …
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a pill save your sight? new trial targets blinding eye disease
Disease control OngoingThis Phase 3 trial tests whether a daily pill called tinlarebant can slow the growth of geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. About 429 adults with the condition will receive either the drug or a placebo for up to 2 year…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New eye drug shows promise for blinding disease
Disease control OngoingThis early-stage trial tests an experimental drug called Kamuvudine-8 (K8) for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 30 participants receive eye injections of K8 and are monitored for 26 weeks to check s…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE1, PHASE2 • Sponsor: Michelle Abou-Jaoude • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Gene therapy trial aims to halt blindness in dry AMD
Disease control OngoingThis study tests a gene therapy called OCU410 for geographic atrophy, a severe form of dry age-related macular degeneration that causes vision loss. About 60 adults aged 50 and older will receive a single injection of OCU410 into the eye. Researchers will monitor safety and check…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE1, PHASE2 • Sponsor: Ocugen • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Sound-Guided gaze: new device aims to sharpen eye imaging for the visually impaired
Symptom relief ENROLLING_BY_INVITATIONThis study tests a device that uses real-time sound feedback to help people with vision loss fix their gaze on a target. Participants hear sounds that guide their eyes back to center when they drift. The goal is to improve the quality of eye imaging by reducing blur from eye move…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: NA • Sponsor: University Medical Center Goettingen • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC